Real-World Study Finds Injectable Obesity Medications Yield Less Weight Loss Than Expected
A Cleveland Clinic study shows that in real-world settings, injectable obesity medications like semaglutide and tirzepatide often produce smaller weight loss due to treatment discontinuation and lower dosages used outside clinical trials.
Recent research from Cleveland Clinic reveals that injectable GLP-1 medications such as semaglutide and tirzepatide, approved for obesity management, tend to produce less weight loss in everyday clinical settings compared to controlled clinical trials. The study highlights that many patients discontinue treatment prematurely or use lower maintenance dosages, which adversely impacts outcomes, including blood sugar control in prediabetic individuals.
The study, published in the Obesity Journal, involved 7,881 adult patients with severe obesity and included a subset with pre-diabetes. Participants started treatment with semaglutide or tirzepatide between 2021 and 2023, but more than 20% discontinued early, and 32% discontinued later, often at lower dosages. On average, patients who ceased treatment early lost only about 3.6% of their body weight after a year, while those who continued late or persisted with higher doses achieved greater weight reductions, with the latter group losing approximately 11.9% to 18% of their body weight.
The study also found that patients who maintained treatment on higher doses experienced more significant weight loss and better blood sugar regulation. Factors linked to achieving a 10% or greater weight loss included continuous medication use, higher doses, female gender, and the use of tirzepatide over semaglutide.
Treatment discontinuation was primarily due to medication costs, insurance issues, side effects, and shortages. Despite weight loss differences, patients who stopped medication maintained relatively stable weight trajectories. The findings suggest that supporting patients in continued treatment and optimizing dosage could lead to better health outcomes.
This research underscores the importance of adherence and dosage in the real-world effectiveness of obesity medications, emphasizing the need for strategies to improve patient retention and compliance for optimal results.
Source: https://medicalxpress.com/news/2025-06-medications-obesity-smaller-weight-loss.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Ultrasound Guidance Reduces IUD Insertion Time Without Increasing Pain
Using ultrasound guidance during IUD insertion significantly reduces procedure time without increasing patient pain, enhancing clinical efficiency and workflow.
Semaglutide Shows Promise in Protecting Against Diabetic Retinopathy
Emerging research suggests that semaglutide, a GLP-1 receptor agonist, may protect against diabetic retinopathy by reducing oxidative stress and promoting retinal cell repair. This could lead to new treatments for preventing vision loss in diabetics.
Unlocking the Human Repairempore: A DNA 'Scar' Catalog to Personalize Cancer Therapy
Discover the 'human repairome,' a comprehensive DNA scar catalog that could revolutionize personalized cancer therapies by revealing how cells repair DNA damage. Developed by CNIO researchers, this resource offers new insights into DNA repair mechanisms and cancer resistance.
Revolutionizing ECG Interpretation by Unlocking the Heart's Hidden Geometry
Scientists at King's College London have discovered how the heart's orientation influences ECG readings, paving the way for more personalized and accurate heart diagnostics using advanced digital twin models.